Cancer drug combination EV+P doubles advanced bladder cancer survival time to 31.5 months in trial.
A cancer drug combination, EV+P (enfortumab vedotin and pembrolizumab), has over doubled the survival time for patients with the most common form of advanced bladder cancer, according to trial results. Patients on EV+P had an average survival rate of 31.5 months, compared to 16.2 months for those on standard chemotherapy. The study, published in the New England Journal of Medicine, marks a significant advancement for bladder cancer patients.
March 11, 2024
4 Articles